- Home
- WNW vs QNTM Comparison
WNW vs QNTM Comparison
Compare WNW & QNTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WNW
- QNTM
- Stock Information
- Founded
- WNW 2015
- QNTM 1998
- Country
- WNW China
- QNTM Canada
- Employees
- WNW N/A
- QNTM N/A
- Industry
- WNW Catalog/Specialty Distribution
- QNTM
- Sector
- WNW Consumer Discretionary
- QNTM
- Exchange
- WNW Nasdaq
- QNTM NYSE
- Market Cap
- WNW 10.1M
- QNTM 8.7M
- IPO Year
- WNW 2020
- QNTM N/A
- Fundamental
- Price
- WNW $1.68
- QNTM $8.04
- Analyst Decision
- WNW
- QNTM
- Analyst Count
- WNW 0
- QNTM 0
- Target Price
- WNW N/A
- QNTM N/A
- AVG Volume (30 Days)
- WNW 51.2K
- QNTM 1.5M
- Earning Date
- WNW 11-15-2024
- QNTM 05-13-2025
- Dividend Yield
- WNW N/A
- QNTM N/A
- EPS Growth
- WNW N/A
- QNTM N/A
- EPS
- WNW N/A
- QNTM N/A
- Revenue
- WNW $380,345.00
- QNTM N/A
- Revenue This Year
- WNW N/A
- QNTM N/A
- Revenue Next Year
- WNW N/A
- QNTM N/A
- P/E Ratio
- WNW N/A
- QNTM N/A
- Revenue Growth
- WNW N/A
- QNTM N/A
- 52 Week Low
- WNW $1.53
- QNTM $2.70
- 52 Week High
- WNW $70.00
- QNTM $44.72
- Technical
- Relative Strength Index (RSI)
- WNW 28.22
- QNTM 60.11
- Support Level
- WNW $1.53
- QNTM $6.45
- Resistance Level
- WNW $3.34
- QNTM $12.45
- Average True Range (ATR)
- WNW 0.29
- QNTM 1.66
- MACD
- WNW 0.15
- QNTM 0.28
- Stochastic Oscillator
- WNW 8.29
- QNTM 43.80
About WNW Meiwu Technology Company Limited
Meiwu Technology Co Ltd operates as an online food retail store and franchise restaurants in China. The products offered include green food, organic food, intangible cultural heritage food products, agricultural products bearing geographical indications, and pollution-free products. It operates in three segments: Clean Food Platform; Restaurant; and Others. The company generates the majority of its revenue from Technical services.
About QNTM QUANTUM BIOPHARMA LTD
Quantum BioPharma Ltd formerly FSD Pharma Inc is a biopharmaceutical company developing three clinical candidates with the potential to address neuropsychiatric, neurodegenerative, and inflammatory disorders. Along with its subsidiaries, the group is focused on pharmaceutical research and development of its compound, FSD201, an ultra-micronized PEA, for the treatment of inflammatory diseases; Lucid-Psych is used in the treatment of mental health disorders and Lucid-MS is used in the treatment of neurodegenerative disorders. The company operates in two segments: Biopharmaceutical and Strategic Investments.